Zusammenfassung
Neuere Untersuchungen der Arbeitsgruppe um Gallo deuten auf die Existenz von Tumor- bzw. Virus-assoziierten Antigenen zumindest bei bestimmten Formen menschlicher Leukämien [13]. Damit wäre eine wichtige theoretische Voraussetzung für ein immuntherapeutisches Konzept menschlicher Leukämien gegeben. Darüber hinaus erfüllt die akute myeloische Leukämie in kompletter Remission (AML in CR) dadurch eine weitere wichtige Voraussetzung für einen immunologischen Therapieansatz [2, 11], daß mit minimalen residualen Tumormassen zu rechnen ist.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Al-Rammahy AK, Shipman S, Jackson A, Malcom A, Levy JG (1980) Evidence for common leukemia-associated antigen in acute myelogenous leukemia. Cancer Immunol Immunother 9: 181–185
Baldwin MA, Robins RA (1978) Factors interferring with immunological rejection of tumors. Br Med Bull 32: 118–123
Bates JG, Suen JY, Tranum BL (1979) Immunological skin testing and interpretation. A plea for uniformity. Cancer 43: 2306–2314
Bekesi JG, Arneault GST, Walter L, Holland JF (1972) Immunogenicity of Leukemia L1210 cells after neuraminidase treatment. J. Natl Cancer Inst 49: 107–118
Bekesi JG, Holland JF, Flemminger R, Yates J, Henderson ES (1977) Immunotherapeutic efficacy of neuraminidase-treated allogeneic myeloblasts in patients with acute myelocytic leukemia. In: Chirigos MA (ed) Control of Neoplasia by modulation of the Immune System, pp 573-592
Bekesi JG, Holland JF, Cuttner J, Silver R, Colman M (1982) Immunotherapy of acute myelocytic leukemia with neuraminidase-modified myeloblasts as immunogen. Proc Am Soc Clin Oncol 1: 36
Büchner Th, Urbanitz D, Hiddemann W, Kamanabroo D, Meister R, Balleisen L, Delvos U, Lagrèze EM, Schmitz-Huebner U, Schulte H, van de Loo J (1979) Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). Blut 39: 133–140
Dutcher JP, Wiernik PH, Van Sloten K, Schiffer CA, Schimpff SC, Aisner J, Angelou JE (1982) Intensive maintenance therapy in acute non-lymphocytic leukemia (ANLL). Abstracts, 3rd International Symposion on Therapy of Acute Leukemias, Roma, 39
Gutterman JU, Rodriguez V, Mavligit G, Burgess MA, Gehan E, Hersh EM, McCredie KB, Reed R, Smith T, Bodey GP, Freireich EJ (1974) Chemoimmunotherapy of adult acute leukemia prolongation of remission in myeloblastic leukemia with B.C.G. Lancet 11: 1406–1409
Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchinson JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK (1981) Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. Blood 58: 1203–1212
Rios A, Simmons RI (1974) Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells. Int J Cancer 13: 71–84
Rühl H, Fülle HH, Koeppen KM, Schwerdtfeger R (1981) Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia. Klin Wochenschr 59: 1189–1193
Schüpbach J, Kalyanaraman VS, Sarngadharan MG, Blattner WA, Gallo RC (1983) Antibodies against three purified proteins of the human type-C retrovirus, human T-cell leukemia-lymphoma virus, in adult T-cell leukemia-lymphoma patients and healthy blacks from the Caribbean. Cancer Res 43: 886–891
Urbanitz D, Büchner Th, Kamanabroo D, Hiddemann W, Schulte H, van de Loo J (1981) Intensified remission induction therapy for acute non-lymphocytic leukemia (ANLL). Treatment report on 60 patients. Blut 43: 119–133
Urbanitz D, Büchner Th, Pielken HJ, Koch P, Hiddemann W, Heinecke A, van de Loo J (1982) Immunotherapy of AML with high dose neuraminidase-treated allogeneic blasts — Preliminary results of a randomized study. Abstracts, 3rd International Symposion on Therapy of Acute Leukemias, Roma 35
Urbanitz D, Büchner Th, Pielken HJ, van de Loo J (1983) Immunotherapy in the treatment of acute myelogenous leukemia (AML): radionale, results and future prospects. Klin Wochenschr 61: 947–954
Vogler WR (1980) Results of randomized trials of immunotherapy for acute leukemia. Cancer Immunol Immunother 9: 15–21
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin, Heidelberg
About this paper
Cite this paper
Pielken, HJ., Urbanitz, D., Büchner, T., Koch, P., Hiddemann, W., van de Loo, J. (1985). Immunotherapie mit allogeneischen Neuraminidasebehandelten viablen Blasten bei akuter myeloischer Leukämie: Therapeutische Daten. In: Aktuelle Aspekte der Tumor-Immunologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70097-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-70097-2_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-13924-9
Online ISBN: 978-3-642-70097-2
eBook Packages: Springer Book Archive